KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.

Mustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, Marina Chiara Garassino, Nenad Medic, Helen Mann, Priti Chugh, Tapashi Dalvi, Luis Paz-Ares

Future Oncol 21(12) 1511-1523

PMID40331625
PMCIDPMC12077470
DOI10.1080/14796694.2025.2491297
发表日期2025-05-07
入排依据:The study is an exploratory analysis of patient-reported adverse events from the CASPIAN trial. While it originates from a Phase III randomized trial with a drug intervention, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The focus is on safety/quality-of-life outcomes, which are excluded per criteria.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 3.:非 KM 图;另有 1 张未列出。
摘要

摘要

AIM: In the phase III CASPIAN study, first-line durvalumab plus platinum-etoposide (EP) improved survival compared with EP in patients with extensive-stage small-cell lung cancer. We report an exploratory analysis of patient-reported adverse events (AEs). METHODS: Of 537 patients randomized to durvalumab + EP or EP arms, 164 were asked to complete the Patient-Reported Outcomes version of the Common Terminology Criteria (PRO-CTCAE) for AEs at baseline, every 3 weeks (q3w) during EP, then q4w until disease progression, then post-progression on day 28, 2 months, and q8w until second progression/death. Presence/absence, frequency, or severity of 11 selected AEs were examined during the first 24 weeks of treatment, alongside interference with usual/daily activities for five AEs. RESULTS AND CONCLUSIONS: A minority of patients reported the examined AEs before starting treatment, from 3-5% who reported hand-foot syndrome, up to 34-41% for dry mouth. AE rates were generally comparable with baseline and the patterns of AEs reported by patients over time were similar in both treatment arms. Most patients indicated that reported AEs occurred rarely/occasionally and were mild/moderate in severity. These PRO-CTCAE data complement the clinician-reported AEs and give insight into patients' experience of treatment. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT03043872.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Compliance with completion of the PRO-CTCAE questionnaire (a) before progression, and (b) at follow-up post progression. Dashed line indicates threshold for acceptable to good compliance (≥60%). Cycle 8 corresponds to approximately 24 weeks.
非 KM Figure
Figure 2.(Continued).
非 KM Figure
Figure 2.Proportion of patients reporting presence or absence, frequency, or severity of AEs in the durvalumab plus EP versus EP arms at each cycle. Reproduced from the poster presented by the authors at the 2022 ASCO annual meeting [ 17 ].
非 KM Figure
Figure 3.Proportion of patients reporting each AE at any visit during the first 24 weeks of treatment, by presence or absence, worst frequency, or worst severity, in the durvalumab plus EP ( n = 79) versus EP ( n = 75) arms.
非 KM Figure
Figure 3.(Continued).
非 KM Figure
Figure 4.Interference of AEs with usual or daily activities at each cycle.
非 KM Figure